Casirivimab And Imdevimab – High Risk Of Treatment Failure Due To Circulation Of Sars-cov-2 Omicron Variant
Recall Summary Casirivimab and Imdevimab, drugs used to treat COVID-19, are being recalled across Canada because the Omicron variant of SARS-CoV-2 has reduced their effectiveness. Patients who have received or are scheduled to receive this treatment are affected by this recall. The drugs may no longer work as intended against the current circulating virus variant.
- Product
- Casirivimab and Imdevimab
- Reason
- New safety information - COVID
- Category
- drug recall
- Country
- Canada
- Agency
- HC-DRUGS
- Recall date
- 2022-01-07
- Status
- Ongoing
- Distribution
- Canada-wide
Official recall notice from HC-DRUGS
Recall details on Nibble Recalls: https://trynibble.app/recalls/b6d742ec-965a-44d8-8f9c-f8274f0886a0